Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III: EFFICACY OF CPX-351 AS FIRST LINE TREATMENT FOR HIGHER RISK (HR) MDS/CMML. A STUDY BY THE GFM. (September 2021) - Peterlin, P.; Turlure, P.; Chevallier, P.; Gourin, M.-P.; Dumas, P.-Y.; Thepot, S.; Berceanu, A.; Park, S.; Hospital, M.-A.; Cluzeau, T.; Torregrossa-Diaz, J.-M.; Devron, L.; et al.